Last reviewed · How we verify
NCT07466810
Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology
NA trial testing Unreal Engine 5 (UE5)-based Mixed Reality (MR) Technology-assisted Resection of Oral Cancer and Defect Reconstruction in Tongue Squamous Cell Carcinoma in 30 participants. Not yet recruiting.
1 April 2027
Quick facts
| Lead sponsor | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 April 2026 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Unreal Engine 5 (UE5)-based Mixed Reality (MR) Technology-assisted Resection of Oral Cancer and Defect Reconstruction
- Virtual Surgical Guide Technology-assisted Resection of Oral Cancer and Defect Reconstruction
Conditions studied
- Tongue Squamous Cell Carcinoma — all drugs for Tongue Squamous Cell Carcinoma →
- Mixed Reality — all drugs for Mixed Reality →
- Virtual Surgical Planning — all drugs for Virtual Surgical Planning →
- Free Flap — all drugs for Free Flap →
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Who can join
Eligibility, any sex, with Tongue Squamous Cell Carcinoma or Mixed Reality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this exploratory clinical trial is to apply Unreal Engine 5 (UE5)-based Mixed Reality (MR) technology to achieve real-time stereoscopic visualization of surgical planning, personalized free flap harvest and defect reconstruction, accurate oral cancer resection, and precise morphological and volumetric matching of the reconstructed free flap to the defect site. Researchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality \[MR\] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group. The primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07466810
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tongue Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
- NCT04333537 — Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cance · Phase 2, PHASE3 · recruiting
Other Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials
Trials by the same sponsor.
- NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
- NCT07505251 — Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Pla · not yet recruiting
- NCT07533695 — Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients · NA · not yet recruiting
- NCT07490561 — The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients · NA · not yet recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07466810 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07466810.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing